Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors

INTRODUCTION: Programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors are standard-of-care treatment for metastatic NSCLC (mNSCLC). Intolerance to treatment/disease progression warrants additional lines of therapy. Real-world treatment patterns and efficacy outcomes after...

Descripción completa

Detalles Bibliográficos
Autores principales: Bains, Savreet, Kalsekar, Anu, Amiri, Katayoun I., Weiss, Jared
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819038/
https://www.ncbi.nlm.nih.gov/pubmed/35146462
http://dx.doi.org/10.1016/j.jtocrr.2021.100275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819038/
https://www.ncbi.nlm.nih.gov/pubmed/35146462
http://dx.doi.org/10.1016/j.jtocrr.2021.100275

Ejemplares similares